> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisors to Consider Lilly’s Baricitinib
- URL: https://www.fdaweb.com/advisors-to-consider-lillys-baricitinib/
- Published: 2018-03-15T12:00:00.000Z
- Updated: 2026-09-14T23:53:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140993

FDA says the Arthritis Advisory Committee will meet 4/23 to discuss Lilly’s NDA for baricitinib tablets. A *Federal* Register [notice](https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-05386.pdf?ref=fdaweb.com) says the company is seeking an indication to treat adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. The panel’s discussion will include the drug’s efficacy; safety, including the risk of thromboembolic adverse events; dose selection; and overall risk/benefit considerations, the notice says. Background materials will be made available no less than two business days before the meeting.